Skip to content

Rich Pharmaceuticals, Inc.: 10-Q filed 2012-03-09

What Rich Pharmaceuticals, Inc. reported in its quarterly report filed 2012-03-09 (fiscal Q3 2011): 12 published measures, 34 facts as tagged in accession 0001255294-12-000168.

This filing

Form
10-Q (quarterly report)
Filed
2012-03-09
Fiscal period
fiscal Q3 2011
Accession
0001255294-12-000168 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Rich Pharmaceuticals, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2011-12-3129,811USD
At 2011-03-3133,811USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2011-12-3129,811USD
At 2011-03-3133,811USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2011-12-3129,811USD
At 2011-03-3129,811USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-04-01 to 2011-12-31-4,000USD275
2010-08-09 to 2011-12-31-22,689USD510

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-04-01 to 2011-12-310USD275
2010-08-09 to 2011-12-31-22,689USD510

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-10-01 to 2011-12-310USD92
2011-04-01 to 2011-12-310USD275
2010-08-09 to 2011-12-310USD510
2010-10-01 to 2010-12-310USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2011-10-01 to 2011-12-31-2,000USD92
2011-04-01 to 2011-12-31-4,000USD275
2010-08-09 to 2011-12-31-22,689USD510
2010-10-01 to 2010-12-310USD92

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-10-01 to 2011-12-312,000USD92
2011-04-01 to 2011-12-314,000USD275
2010-08-09 to 2011-12-3122,689USD510
2010-10-01 to 2010-12-310USD92

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2011-12-3149,875USD
At 2011-03-3149,875USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2011-12-310USD
At 2011-03-310USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-10-01 to 2011-12-310USD92
2011-04-01 to 2011-12-310USD275
2010-08-09 to 2011-12-31320USD510
2010-10-01 to 2010-12-310USD92

Current income tax expense or benefit

Income tax expense or benefit for the period that is currently payable or refundable. It differs from cash taxes paid and from total tax expense.

PeriodValueUnitDays
2011-10-01 to 2011-12-310USD92
2011-04-01 to 2011-12-310USD275
2010-08-09 to 2011-12-310USD510
2010-10-01 to 2010-12-310USD92

Inspect the source

Entity
Rich Pharmaceuticals, Inc. / CIK 0001504389
Captured
SEC response SHA-256
915b548928758b0cd7825b62d7fc36ff2ecd50f0e88985055b0b19ae94428b67

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001504389.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))